January 2023 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
Amjevita is supplied as a 40mg/0.8mL single-dose prefilled SureClick autoinjector, and as 20mg/0.4mL and 40mg/0.8mL single-dose prefilled syringes.
The NDA is supported by two 2 positive interim analyses from the phase 3 REGENERATE trial that included patients with biopsy-proven stage 2 or 3 liver fibrosis due to NASH.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Researchers addressed common misconceptions regarding the diagnosis and treatment of gastroparesis.
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
The randomized, double-blind, multicenter PHALCON-NERD-301 study included 776 adults with symptomatic NERD.
The FDA has established an acceptable daily intake limit for NVP of 96ng/day.
More patients receiving dupilumab have histologic remission, improvement in Dysphagia Symptom Questionnaire scores
Etrasimod is an oral selective sphingosine 1-phosphate (S1P) receptor modulator currently being investigated to treat a range of immuno-inflammatory diseases.